Patent · US Active

Compounds and compositions as kinase inhibitors

US8518931B2 · kind B2 · utility

6Cited by
1References
19Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 3, 2009
Grant dateAug 27, 2013
Priority date
Expiry dateOct 28, 2029

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to triazine and pyrimidine derivatives having Formula (1) or (2), and methods for using such compounds. For example, the compounds of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-IR), and/or insulin receptor (InsR) or a combination thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.